Tafenoquine

First discovered in 1978 at the Walter Reed Army Institute of Research, Tafenoquine (TQ) was recently approved by the United States Food and Drug Administration for use as the first new single-dose for the radical treatment of P. vivax malaria in over 60 years [56]. TQ is thought to be a prodrug which is metabolized to the active quinone TQ, however, the MoA is not well known [57]. It is currently sold under the brand name Krintafel.